OneCell Diagnostics raised $16 million in a Series A funding round led by Celesta Capital to advance their precision oncology liquid biopsy diagnostics.
Cedars SinaiTenacity VenturesEragonSingularity VenturesCelesta Capital
Description
OneCell Diagnostics, an AI-powered cancer diagnostics startup, raised $16 million in an oversubscribed Series A funding round. The funding will be used to democratize precision oncology through accessible cancer testing and to expand into the US market with their next-generation liquid biopsy test, OncoIndx Alfa.
Who to call at OneCell Diagnostics, and when
A new round usually means OneCell Diagnostics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day OneCell Diagnostics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at OneCell Diagnostics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
OneCell Diagnostics
Location
Pune, Maharashtra, India
About
OneCell Diagnostics, Inc. is a Precision Oncology Liquid Biopsy Diagnostics Company focused on developing the 1st-in-Class, Circulating Tumor Cell (CTC)-based, Single-Cell Multi-omics Lab Developed Tests for applications in clinical cancer care & early-stage clinical trials for Biotech/Pharma companies.
OneCell Diagnostics, Inc. is a joint venture between two companies with innovative technologies: Actorius Innovations and Research Pvt Ltd, a leading provider of CTC Tests in India, and Indx.ai, a Silicon Valley based innovative software company specialising in Multi-omics Biomarker Data Analytics.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment OneCell Diagnostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
PuneBiotechnologyHealth CareArtificial IntelligenceMedicalHealth Diagnostics